Efficacy of Meropenem as Monotherapy in the Treatment of Ventilator-Associated Pneumonia

REFERENCES

• TabIan OC, Anderson L,J, Arden NH, Breiman RF, Butler JC, McNeil MM. Centers for Disease Control and Prevention. Guideline for prevention of nosocomial pneumo-nia. Infect Control Hosp Epidemiol 1994; 15: 587–625.
   Google Scholar
• National Nosocomial Infections Surveillance (NNIS) Report. Data summary from October 1986-April 1997. Am J Infect Control 1997; 25: 477–487.
   PubMedGoogle Scholar
• Torres A, Aznar R, Gatell JM, et al. Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 523–528.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma FM, Palomar M, Martinez-Pellus A, Alvarez-Sanchez B, Perez-Ortiz E, Jorda R and the ICU-acquired Pneumonia Study Group. Aetiology and diagnostic techniques in intensive care-acquired pneumonia: a Spanish multi-centre study. Clin Intensive Care 1997; 8: 164–170.
   Google Scholar
• Potgeier PD, Hammond JMJ. Etiology and diagnosis of pneumonia requiring ICU-admission. Chest 1992; 101: 199–203.
   PubMed Web of Science ®Google Scholar
• Rello J, Ausina V, Ricart M, Custella, Prats G. Impact of previous antimicrobial therapy on etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: 1230–1235.
   PubMed Web of Science ®Google Scholar
• Van Saene HKF, Damjanovic V, Silvestri L, de la Cal MA. Classification of infections. In Van Saene HKF, Silvestri L, de la Cal MA, eds. Infection Control in the Intensive Care Unit. Springer-Verlag Italia, Milano: 1998; 17-28.
   Google Scholar
• Kollef M, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. Chest 1999; 115: 462–474.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F. Modification of empiric antibiotic treat-ment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22: 387–394.
   PubMed Web of Science ®Google Scholar
• Unertl KE, Lenhart FP, Forst H, Peter K. Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med 1992; 18: 28S-34S.
   Google Scholar
• Niederman MS, Campbell GD, Broughton WA et al. Guideline for the initial empiric management of adults with hospital-acquired pneumonia: diagnosis assessment of severity, initial antimicrobial therapy and prevention strategies. Am J Respir Crit Care Med 1996; 153: 1711–1725.
   Google Scholar
• Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999; 281: 67–71.
   PubMed Web of Science ®Google Scholar
• Lucet JC, Chevret S, Decré D et al. Outbreak of multi-ply resistant Enterobacteriaceae in an intensive care unit: epi-demiology and risk factors for acquisition. Clin Infect Dis 1996; 22: 430–436.
   Google Scholar
• Blumer JL. Meropenem: evaluation of a new genera-tion carbapenem. Int J Antimicrob Agents 1997; 8: 73–92.
   PubMed Web of Science ®Google Scholar
• Norrby SR, Faulkner KL, Newell PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract 1997; 6: 291–303.
   Web of Science ®Google Scholar
• Edwards JR, Turner PJ. Laboratory data which differen-tiate meropenem and imipenem. Scand J Antimicrob Chemother 1989; 24 ( Suppl A): 5-10.
   Google Scholar
• Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997; 28: 157–163.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (meropenem yearly susceptibility test informa-tion collection) programme. Int J Antimicrob Agents 1999; 13: 117–125.
   PubMed Web of Science ®Google Scholar
• Hamacher J, Vogel F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease on hospitalised patients: a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995; 36: 121–133.
   PubMed Web of Science ®Google Scholar
• Garau J, Blanquer J, Cobo L, et al. Prospective, ran-domised multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe noso-comial infections. Eur J Clin Microbiol Infect Dis 1997; 16: 789–796.
   PubMed Web of Science ®Google Scholar
• Berman SJ, Sieger B, Geckler RW, Farkas SA. A com-parative study of meropenem and ceftazidime in the treatment of patients hospitalised with community-acquired pneumonia. Curr Ther Res 1997; 58: 903–916.
   Web of Science ®Google Scholar
• Mouton YJ, Beuscart C and the Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36: ( Suppl A): 145-156.
   Google Scholar
• Colardyn F, Faulkner KL, for the Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilistatin in the treatment of serious bacterial infec-tions in hospitalised patients. J Antimicrob Chemother 1996; 38: 523–537.
   Google Scholar
• Sieger B, Berman SJ, Geckler RW, Farkas SA, for the Meropenem Lower Respiratory Infection Group. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a random-ized study. Crit Care Med 1997; 25: 1663–1670.
   Google Scholar
• Wimberley N, Failing LI Bartlett JG. A fiberoptic bron-choscopy technique to obtain uncontaminated lower airway secretion for bacterial culture. Am Rev Respir Dis 1979; 119: 337–343.
   Google Scholar
• Reynolds HY. Bronchoalveolar lavage. Am Rev Respir Dis 1987; 135: 250–263.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacte-ria that grow aerobically. 1993. NCCLS, Villanova, PA. Approved Standard, Document M7-A3.
   Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–829.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Sonet JP, Schweich H, Bribre S, Petit C, for the VAP Study Group. Treatment of ventilator assisted pneumonia with piperacillin-tazobactam/amikacin versus cef-tazidime/amikacin: A multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346–354.
   Google Scholar
• Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38: 547–557.
   PubMed Web of Science ®Google Scholar
• Mehtar S, Dewar EP, Leaper DJ, Taylor EW. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997; 39: 631–638.
   PubMed Web of Science ®Google Scholar
• Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1996; 38: 1309–1313.
   Web of Science ®Google Scholar
• Silver DR, Cohen IL, Weinberg OF. Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. Chest 1992; 101: 194–198.
   PubMed Web of Science ®Google Scholar